Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.58 |
| ▸ | HAO2 | Q9NYQ3 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403299 | 0.87 | HCAR2 (0.43) | HCAR2 | |
| SCHEMBL4185273 | 0.80 | ALOX15 (0.44) | HCAR2 | |
| SCHEMBL3129263 | 0.74 | HCAR2 (1.00) | HCAR2HAO2DAO | |
| SCHEMBL570053 | 0.73 | HCAR2 (0.50) | HCAR2 | |
| SCHEMBL4631308 | 0.73 | HCAR2 (0.63) | HCAR2HAO2DAO | |
| Hydrochloric Acid SCHEMBL19556304 | 0.72 | HCAR2 (0.96) | HCAR2HAO2DAO | |
| SCHEMBL21711399 | 0.70 | DYRK1A (0.46) | HCAR2 | |
| SCHEMBL948870 | 0.69 | HCAR2 (1.00) | HCAR2HAO2DAO | |
| SCHEMBL29954524 | 0.69 | HCAR2 (0.59) | HCAR2HAO2DAO | |
| SCHEMBL28634164 | 0.69 | HCAR2 (0.59) | HCAR2HAO2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-2935248-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2935248-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-12-07 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676748-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-13 | — | — | US | disclosed |
| CN-105308036-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2016-02-03 | — | — | CN | disclosed |
| EP-2935248-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014100620-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100620-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213554-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | HCAR2 2224/4885HAO2 4312/4885DAO 2243/4885 |
| US-10301280-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | HCAR2 2224/4885HAO2 4312/4885DAO 2243/4885 |
| US-20170349572-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | HCAR2 2224/4885HAO2 4312/4885DAO 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.